Trial Profile

A Phase 1 Open-label Study Evaluating the Pharmacokinetics and Mass Balance of [14C] TAS-205 in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pizuglanstat (Primary)
Indications Duchenne muscular dystrophy
Focus Pharmacokinetics
Sponsors Taiho Pharmaceutical

Most Recent Events

01 Mar 2025 Results characterizing the absorption, metabolism, and excretion of carbon-14 (14C)-labeled pizuglanstat in healthy adults published in the Clinical Pharmacology in Drug Development.
04 Aug 2022 Status changed from active, no longer recruiting to completed.
13 Aug 2021 Status changed from not yet recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com